C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
C4 Therapeutics will share new T-cell and NK-cell biomarker findings for cemsidomide plus dexamethasone in RRMM at the 2026 IMS meeting.
Rhea-AI Summary
C4 Therapeutics (CCCC) will present new biomarker data from its Phase 1 trial of cemsidomide plus dexamethasone in relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting.
The poster will detail immunomodulatory effects on T cells and natural killer (NK) cells across once-daily dose levels evaluated in the study, which the company says further support cemsidomide’s potential as a combination partner for immune-based therapies. The meeting will be held in Glasgow, Scotland from September 23–26, 2026.
The poster, titled “T- And NK-Cell Immunomodulatory Reprogramming By Cemsidomide, A Novel And Potent MonoDAC® Degrader, In Relapsed/Refractory Multiple Myeloma: Biomarker Results From CFT7455-1101 Arm B2 Cohort,” is scheduled for September 25, 2026, from 12 pm–1 pm BST / 7 am–8 am ET and will be presented by Riadh Lobbardi, Ph.D., Senior Director of Translational Medicine at C4 Therapeutics.
Positive
- None.
Negative
- None.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Phase 1 clinical data | Positive | +0.0% | Updated cemsidomide response and safety data presented at EHA 2026 |
| Feb 23 | Phase 2 trial start | Positive | +6.5% | First patient dosed in the Phase 2 MOMENTUM multiple myeloma trial |
| Oct 01 | Clinical trial collaboration | Positive | -3.1% | Pfizer collaboration formed for cemsidomide and elranatamab combination |
| Sep 20 | Phase 1 clinical data | Positive | -17.4% | Cemsidomide multiple myeloma data presented at IMS annual meeting |
| Dec 08 | Phase 1 clinical data | Positive | -5.2% | Cemsidomide response data presented at ASH annual meeting |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical-trial announcements were usually followed by negative or flat 24-hour reactions despite positive trial content: four of five diverged, with a tag-specific average move of -3.86%.
Key Terms
targeted protein degradation technical
biomarker medical
immunomodulatory medical
natural killer cells medical
relapsed/refractory multiple myeloma medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting. The data characterize the immune effects on T cells and natural killer (NK) cells across the once-daily dose levels evaluated in the Phase 1 trial, further supporting cemsidomide’s potential as a combination partner for immune-based therapies. The meeting will take place in Glasgow, Scotland from September 23 – 26, 2026.
Poster Presentation Details:
Title: T- And NK-Cell Immunomodulatory Reprogramming By Cemsidomide, A Novel And Potent MonoDAC® Degrader, In Relapsed/Refractory Multiple Myeloma: Biomarker Results From CFT7455-1101 Arm B2 Cohort.
Presentation Date and Time: September 25, 2026, from 12 pm – 1 pm BST / 7 am – 8 am ET
Presenter: Riadh Lobbardi, Ph.D., Senior Director of Translational Medicine, C4 Therapeutics
About Cemsidomide
Cemsidomide is an investigational, next-generation orally bioavailable MonoDAC® degrader (molecular glue) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the fully enrolled Phase 1 trial show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that supports the potential for durable outcomes.
About Multiple Myeloma
Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow. It is the second most common blood cancer, with approximately 36,000 people in the United States diagnosed each year. Multiple myeloma is characterized by cycles of remission and relapse, which leads to patients needing multiple lines of therapy to manage the persistent disease. More than 175,000 patients in the United States are estimated to be living with or in remission from myeloma. However, despite treatment advances, approximately
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
